Case Studies
Client Situation
A midsize biopharma client wanted to create a rep-centric tool to help them understand their targets and map against current performance and gaps, identify changes in market scenario, manage schedules, prioritize targets and deliver contextual content
Trinity’s Role
Trinity developed a comprehensive field force tool to track target treatment paradigms, analyze market drivers and identify Next Best Actions (NBAs)
Integrated tightly with rep calendars to provide triggers with insights and recommendations contextual to rep schedules
Leveraged multiple data…
Read Now
Webinars
Available On Demand
There are four key pieces to Patient Finding:
Identifying, collating and integrating the right data
Defining the appropriate test population
Building the right features in the model
Planning and executing actions once you’ve found the patients
All four are crucial to successfully find patients. Join Adrienne Lovink, Partner and Head of Real-World Evidence (RWE) at Trinity Life Sciences, as she hosts a lively discussion on the ins and outs of Patient Finding with Trinity panelists Steve Laux, Vice President of…
Watch Now
Blog
Published July 21, 2023
For life sciences companies focused on rare diseases, accurate patient finding is a worthy challenge—one deserving dedicated time and resource to tackling and solving. The benefit of enrolling even one new patient is large, both for the lives of patients in need and the commercial success of the therapies.
Why is patient finding in rare disease such a challenge?
The hallmarks of a rare disease work against traditional targeting methods: small patient population sizes, complex disease recognition, lengthy roads to…
Read Now
Case Studies
Background
A global rare disease company was looking to improve targeting precision and support field team effectiveness
Traditional targeting was non-viable due to the small size of the patient populations, complex disease recognition and diagnosis, and restrictive therapy eligibility criteria
Attempts by a prior analytics partner to use rule-based alerts failed, and even after two years, no new patients had been identified
Given the small number of patients in each indication, every new start is high value, both for the…
Read Now
